ReviewDrug discovery today2015
Computational systems biology approaches to anti-angiogenic cancer therapeutics.
Review in Drug discovery today, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present.Journal of ovarian research · 2022Pooled it
- Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies.ACS pharmacology & translational science · 2023Article
- Quantitative medicine: Tracing the transition from holistic to reductionist approaches. A new "quantitative holism" is possible?Journal of public health research · 2023Article
- Axl and Vascular Endothelial Growth Factor Receptors Exhibit Variations in Membrane Localization and Heterogeneity Across Monolayer and Spheroid High-Grade Serous Ovarian Cancer Models.GEN biotechnology · 2023Article
- NF-kB in Signaling Patterns and Its Temporal Dynamics Encode/Decode Human Diseases.Life (Basel, Switzerland) · 2022Review
- Systems biology of angiogenesis signaling: Computational models and omics.WIREs mechanisms of disease · 2022Review
- Current status of cancer starvation therapy.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- Article
- The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer.Cancers · 2021Review
- Cerebrovascular development: mechanisms and experimental approaches.Cellular and molecular life sciences : CMLS · 2021Review
- A multiscale model of complex endothelial cell dynamics in early angiogenesis.PLoS computational biology · 2021Article
- Multiscale modeling of tumor response to vascular endothelial growth factor (VEGF) inhibitor.In silico biology · 2021Article
- The Convergence of Cell-Based Surface Plasmon Resonance and Biomaterials: The Future of Quantifying Bio-molecular Interactions-A Review.Annals of biomedical engineering · 2020Review
- Sex differences in cancer mechanisms.Biology of sex differences · 2020Review
- Systems Pharmacogenomic Landscape of Drug Similarities from LINCS data: Drug Association Networks.Scientific reports · 2019Article
- Mechanistic Computational Models of MicroRNA-Mediated Signaling Networks in Human Diseases.International journal of molecular sciences · 2019Review
- Exploring the Extracellular Regulation of the Tumor Angiogenic Interaction Network Using a Systems Biology Model.Frontiers in physiology · 2019Article
- The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.Integrative biology : quantitative biosciences from nano to macro · 2018Article
- Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.Clinical and experimental immunology · 2018Article
- Harnessing the biological complexity of Big Data from LINCS gene expression signatures.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Angiogenesis is an exquisitely regulated process that is required for physiological processes and is also important in numerous diseases. Tumors utilize angiogenesis to generate the vascular network needed to supply the cancer cells with nutrients and oxygen, and many cancer drugs aim to inhibit tumor angiogenesis. Anti-angiogenic therapy involves inhibiting multiple cell types, molecular targets, and intracellular signaling pathways. Computational tools are useful in guiding treatment strategies, predicting the response to treatment, and identifying new targets of interest. Here, we describe progress that has been made in applying mathematical modeling and bioinformatics approaches to study anti-angiogenic therapeutics in cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.